The PAM50 subtypes were calculated for all samples, showing the highest percentage of patients as Luminal A (36%) and Luminal B (30%), with a small population of Basal-like (17%) and HER2-Enriched (17%) samples.  The PAM50 subtypes displayed the well-established phenotype biology, as seen on the PAM50 Subtyping Analysis tab. Patients with Luminal B and HER2-Enriched had longer survival on the combination therapy than typically seen in the literature when patients are on standard of care alone.  Basal-Like patients had the poorest survival on the combination therapy when compared to standard of care, however, the Basal-Like survival was increased over the literature for standard of care.